NCT02704858View on ClinicalTrials.gov

Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

August 1, 2017

Primary Completion Date

October 31, 2025

Study Completion Date

December 31, 2025

Conditions
Glioblastoma Multiforme
Interventions
DRUG

Perillyl alcohol

Intranasal administration

Trial Locations (9)

10016

RECRUITING

Northwell Health, New York

27157

RECRUITING

Wake Forest University Health Sciences, Winston-Salem

30912

RECRUITING

Georgia Cancer Center (Augusta University), Augusta

44333

RECRUITING

Cleveland Clinic, Cleveland

70121

RECRUITING

Ochsner Health, New Orleans

75061

WITHDRAWN

Baylor Scott & White Health, Dallas

75235

RECRUITING

University of Texas Southwestern Medical Center, Dallas

90033

RECRUITING

University of Southern California, Los Angeles

07901

RECRUITING

Atlantic Health (Overlook Medical Center), Summit

Sponsors
All Listed Sponsors
lead

Neonc Technologies, Inc.

INDUSTRY

NCT02704858 - Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma | Biotech Hunter | Biotech Hunter